Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians

The sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce risks of clinical events in patients with heart failure (HF), with early and sustained benefits regardless of ejection fraction, diabetic status, and care setting. As part and parcel of the modern foundational HF therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Monzo, Luca, Ferrari, Ilaria, Cicogna, Francesco, Tota, Claudia, Cice, Gennaro, Girerd, Nicolas, Calò, Leonardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
PLACE 2022 Supplement Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132577/
https://www.ncbi.nlm.nih.gov/pubmed/37125324
http://dx.doi.org/10.1093/eurheartjsupp/suad055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132577/
https://www.ncbi.nlm.nih.gov/pubmed/37125324
http://dx.doi.org/10.1093/eurheartjsupp/suad055

Ejemplares similares